Sarepta shares gained even though the U.S. Food and Drug Administration said late Friday that it was probing the death of an ...

The Trump FDA tries to kill a therapy that has helped boys with a deadly diagnosis.

In its own communique issued shortly after the FDA’s, Sarepta elaborated on the situation and confirmed a Roche statement to ...

Sarepta Therapeutics Inc. (NASDAQ:SRPT) is one of the most undervalued stocks to buy and hold for 3 years. On July 22, BMO ...

Brazilian authorities said the death was unlikely to have been caused by Elevidys and was instead more in line with severe ...

The FDA is investigating the death of an 8-year-old boy who received Elevidys, a gene therapy developed by Sarepta Therapeutics to treat Duchenne muscular dystrophy. The child died June 7, prompting ...

Sarepta Therapeutics now trades at book value with strong cash and cost-cutting plans, while ELEVIDYS may regain broader use.

Sarepta Therapeutics (SRPT) shares dropped sharply on Monday following news that the FDA is investigating a patient death potentially connected to its gene therapy, Elevidys.

The Food and Drug Administration is investigating Sarepta’s gene therapy products following reports of a third death from acute liver failure.

When Pasadena-based Arrowhead Pharmaceuticals Inc. signed a huge licensing and collaboration deal with Cambridge, ...

The US Food and Drug Administration (FDA) issued a press release late Friday announcing an investigation into the death of an ...